EVO756 demonstrated an excellent safety profile and was well tolerated at all doses; pharmacokinetic data supports once-daily oral dosing EVO756 is a potent and highly selective small molecule antagonist of MRGPRX2 Evommune to initiate multiple Phase 2 trials PALO ALTO, Calf., July 16,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.